000 01377 a2200325 4500
005 20250517062434.0
264 0 _c20170119
008 201701s 0 0 spa d
022 _a2171-8695
024 7 _a10.7399/fh.2015.39.5.8981
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGonzález Chávez, Jenifer
245 0 0 _a[Vedolizumab in Crohn Disease genesis-sefh drug evaluation report].
_h[electronic resource]
260 _bFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
_cSep 2015
300 _a297-308 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAntibodies, Monoclonal, Humanized
_xeconomics
650 0 4 _aCrohn Disease
_xdrug therapy
650 0 4 _aDrug Evaluation
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xeconomics
650 0 4 _aMulticenter Studies as Topic
650 0 4 _aRandomized Controlled Trials as Topic
700 1 _aAsensi Diez, Rocio
700 1 _aTamayo Bermejo, Rocío
700 1 _aAlegre Del Rey, Emilio Jesús
700 1 _aMartínez López de Castro, Noemí
773 0 _tFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
_gvol. 39
_gno. 5
_gp. 297-308
856 4 0 _uhttps://doi.org/10.7399/fh.2015.39.5.8981
_zAvailable from publisher's website
999 _c25428481
_d25428481